This portrait of Genentech's chief of clinical trials borders on hagiography.
No mention that Genentech spent millions in legal fees (> $100 million by all parties according to a WSJ article reprinted here) keeping an effective treatment for food allergy off the market.
That drug, made by Tanox, is very similar to Omalizumab (Xolair) an antibody against IgE (IgE or immunoglbulin E which is the antibody that causes allergies) but Xolair hasn't been approved (or studied) for food allergy. I'm not a believer in this approach (too expensive and it only prevents reactions as opposed to treating the underlying allergy).
You think the article could at least mentioned this, as it does present something of an issue for a physician who, per the article, is so "attenuated to the feelings of patients."